Arch Therapeutics Inc (ARTH)

[Regis999]

IMHO $ARTH is most unusual from the standpoint of tiny capital to be committed or raised to reach the endzone for completion of human trials and be acquired. Tiny.

Since going public in 2013 $ARTH has raised $ 24,207,274. As you know Curam is assisting in funding in Europe trials.

Show me another biotech that requires so little capital to success?

I estimate that approximately $ 5 to $ 7 million of additional capital will be required for competition of all human trials. I am hoping whoever does the European JV (Johnson & Johnson, Baxter) will put up a large up front fee.